Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993).
出版信息
Br J Clin Pharmacol. 1994 Aug;38(2):95-7. doi: 10.1111/j.1365-2125.1994.tb04330.x.
Abstract
摘要
相似文献
1
Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993).公司资助的上市药品安全性评估指南（SAMM指南）。药品控制局、药品安全委员会、皇家全科医师学院、英国医学协会和英国制药工业协会（1993年11月）
Br J Clin Pharmacol. 1994 Aug;38(2):95-7. doi: 10.1111/j.1365-2125.1994.tb04330.x.
2
Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed.为什么需要已上市药品安全评估（SAMM）指南。
Br J Clin Pharmacol. 1994 Aug;38(2):93. doi: 10.1111/j.1365-2125.1994.tb04329.x.
3
Review of company postmarketing surveillance studies.公司上市后监测研究综述。
BMJ. 1992 Jun 6;304(6840):1470-2. doi: 10.1136/bmj.304.6840.1470.
4
New horizons in post-marketing surveillance.上市后监测的新视野。
Health Trends. 1993;25(3):83.
5
Recalls. FDA, industry cooperate to protect consumers.召回。美国食品药品监督管理局与企业合作保护消费者。
FDA Consum. 1995 Oct;29(8):24-7.
6
Code of practice for the clinical assessment of licensed medicinal products in general practice.全科医疗中已上市药品临床评估的实践规范。
Br Med J (Clin Res Ed). 1983 Apr 16;286(6373):1295-7. doi: 10.1136/bmj.286.6373.1295.
7
Drug regulation in the United Kingdom.英国的药品监管
Clin Pharmacol Ther. 1976 May;19(5 Pt 2):689-93. doi: 10.1002/cpt1976195part2689.
8
The compensation of patients injured in clinical trials.临床试验中受伤害患者的补偿。
J Med Ethics. 1995 Jun;21(3):166-9. doi: 10.1136/jme.21.3.166.
9
Food and drugs: why different approaches to their safety?食品与药品：为何对它们的安全采取不同的方法？
Lancet. 1984 May 19;1(8386):1116. doi: 10.1016/s0140-6736(84)92522-4.
10
The need for human data: the role of clinical trials and postmarketing surveillance in the safety assessment of macronutrient substitutes.人类数据的需求：临床试验和上市后监测在大量营养素替代品安全性评估中的作用。
Regul Toxicol Pharmacol. 1996 Feb;23(1 Pt 2):S20-1; discussion S31-7. doi: 10.1006/rtph.1996.0019.
引用本文的文献
1
Mortality study of 18 000 patients treated with omeprazole.对18000名接受奥美拉唑治疗的患者进行的死亡率研究。
Gut. 2003 Jul;52(7):942-6. doi: 10.1136/gut.52.7.942.
2
Determinants of headache in lansoprazole users in The Netherlands: results from a nested case-control study.荷兰兰索拉唑使用者头痛的决定因素：一项巢式病例对照研究的结果
Drug Saf. 2002;25(4):287-95. doi: 10.2165/00002018-200225040-00005.
3
Prescribing patterns in patients using new antidepressants.使用新型抗抑郁药患者的用药模式。
Br J Clin Pharmacol. 2001 Feb;51(2):181-3. doi: 10.1111/j.1365-2125.2001.01329.x.
4
Postmarketing surveillance study of a non-chlorofluorocarbon inhaler. Such studies initiated by manufacturer are designed to promote product.一种不含氯氟烃吸入器的上市后监测研究。制造商发起的此类研究旨在推广产品。
BMJ. 1999 Mar 20;318(7186):810, author reply 810-11.
5
Pharmacovigilance in the pharmaceutical industry.制药行业中的药物警戒
Br J Clin Pharmacol. 1998 May;45(5):427-31. doi: 10.1046/j.1365-2125.1998.00713.x.
本文引用的文献
1
Review of company postmarketing surveillance studies.公司上市后监测研究综述。
BMJ. 1992 Jun 6;304(6840):1470-2. doi: 10.1136/bmj.304.6840.1470.
Zotero 插件